Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026
Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Fineline Cube Aug 7, 2026
Company Drug

BeOne Medicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma

Fineline Cube Oct 14, 2025

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food...

Company Drug

ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX‑117, Targeting Charcot‑Marie‑Tooth Disease

Fineline Cube Oct 14, 2025

ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan...

Company Drug

Everest Medicines Commences Global Phase I Trial of Universal mRNA Cancer Vaccine EVM14

Fineline Cube Oct 14, 2025

Everest Medicines Limited (HKG: 1952) announced today that the first patient has been successfully dosed...

Company Deals Drug

Boehringer Ingelheim Launches Trajenta Production in Zhangjiang, China

Fineline Cube Oct 14, 2025

Boehringer Ingelheim (BI) announced today the official start‑up of its local manufacturing plan for the diabetes...

Company Drug

Amoytop Biotech Secures NMPA Approval for Pegbinterferon Combination Therapy in Chronic Hepatitis B

Fineline Cube Oct 13, 2025

Amoytop Biotech Co. Ltd. (SHA: 688278) announced today that the National Medical Products Administration (NMPA)...

Company Deals

Sihuan Pharma Invests in Swiss Aesthetic Tech Company Suisselle, Secures Permanent Exclusive Distribution of CELLBOOSTER in China

Fineline Cube Oct 13, 2025

Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that it has completed an equity...

Company Drug

Sino Biopharma Subsidiary Secures Breakthrough Therapy Designation for TQB2102 ADC Targeting HER2‑Positive Colorectal Cancer

Fineline Cube Oct 13, 2025

Jiangsu Chia Tai  Tianqing Pharmaceutical Co., Ltd. (CTTQ), a wholly‑owned subsidiary of China‑listed Sino Biopharmaceutical Ltd....

Company Drug

Everest Medicines Receives NMPA Approval for Universal Oncology Vaccine EVM14

Fineline Cube Oct 13, 2025

Everest Medicines Limited (HKG: 1952) announced today that the National Medical Products Administration (NMPA) has...

Company Drug

Sichuan Kelun‑Biotech Wins NMPA Approval for Sacituzumab‑Tirumotecan in EGFR‑Mutant Lung Cancer

Fineline Cube Oct 13, 2025

China‑listed Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced today that the National Medical Products...

Company Drug

Beihai Biotech Secures FDA IND Approval for First‑In‑Class Peptide‑Drug Conjugate BH1621

Fineline Cube Oct 13, 2025

China‑based Zhuhai Beihai Biotech Co., Ltd. announced today that its Category 1 innovative drug BH1621 has...

Company Deals

Sichuan Biokin’s SystImmune Receives $250 Million Triggered by Phase 2/3 Milestone in EGFR×HER3 ADC

Fineline Cube Oct 13, 2025

China‑based Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its wholly‑owned subsidiary SystImmune, Inc....

Drug

Boehringer Ingelheim Secures FDA Approval for Nerandomilast (JASCAYD) in Idiopathic Pulmonary Fibrosis

Fineline Cube Oct 13, 2025

Boehringer Ingelheim (BI) announced today that the U.S. Food and Drug Administration (FDA) has approved...

Drug

China’s NMPA Approves Mufemilast (Hemay005) — Hemei’s First Domestic PDE4 Inhibitor

Fineline Cube Oct 13, 2025

The National Medical Products Administration (NMPA) announced that Jiangxi Hemei Pharmaceutical Co., Ltd. has received...

Drug Medical Device Policy / Regulatory

State Council Introduces 2026 Regulations Governing Clinical Research of Biomedical New Technologies in China

Fineline Cube Oct 13, 2025

The Chinese State Council has issued the Regulations on the Administration of Clinical Research and...

Company Deals Drug

BMS Acquires Orbital for $1.5 B in RNA‑Based Immunotherapy Deal

Fineline Cube Oct 11, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced today that it will acquire Orbital Therapeutics (“Orbital”), a...

Company Medical Device

Peijia Medical Secures NMPA Approval for GeminiOne TEER System

Fineline Cube Oct 11, 2025

Peijia Medical Limited (HKG: 9996) announced today that the National Medical Products Administration (NMPA) of...

Company Deals Drug

PegBio Signs Non‑Binding Term Sheet with UAE‑Based PDC for Exclusive Middle East & Africa License of Visepegenatide

Fineline Cube Oct 11, 2025

PegBio Co., Ltd. (HKG: 2565) announced today that it has entered into a non‑binding term...

Company Deals

Tigermed Completes Share Transfer of Teddy Clinical Laboratory to Frontage Laboratories for RMB 270 Million

Fineline Cube Oct 11, 2025

China‑based Hangzhou Tigermed Consulting Co., Ltd. (HKG: 3347) announced that it and its subsidiary Jiaxing...

Company Legal / IP

BeOne Medicines Terminates Patent Dispute with AbbVie’s Pharmacyclics Over BTK Inhibitors

Fineline Cube Oct 11, 2025

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that it has terminated...

Company Drug Policy / Regulatory

National Drug Alliance Moves VBP 11th‑Round Information Disclosure Conference to 27 Oct 2025 in Shanghai

Fineline Cube Oct 11, 2025

The National Drug Alliance Procurement Office announced a schedule change for the 11th round of...

Posts pagination

1 … 134 135 136 … 705

Recent updates

  • CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
  • Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction
  • Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
  • Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis
  • Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Company Drug

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.